Unique Characteristics of AAV1, 2, and 5 Viral Entry, Intracellular Trafficking, and Nuclear Import Define Transduction Efficiency in HeLa Cells
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Biological differences between recombinant adeno-associated virus (rAAV) serotypes define their efficiencies in expressing a transgene in a particular target cell. Few studies have directly compared how differences in viral entry, intracellular trafficking, and nuclear import of rAAV serotypes influence the effectiveness of transduction in the same cell type. We evaluated these characteristics for three rAAV serotypes in HeLa cells, using biochemical techniques and fluorescence-based detection of multiple serotypes in the same cell. Although rAAV2 exhibited the slowest entry, intracellular trafficking, and nuclear import among the three serotypes, it elicited the highest levels of transduction. Conversely, rAAV1 exhibited more rapid entry and nuclear import than the other serotypes, yet was ineffective at transducing HeLa cells due to impaired capsid disassembly in the nucleus. rAAV5, which entered the cell less rapidly than rAAV1, was imported efficiently into the nucleus, but then rapidly degraded, resulting in poor transduction of HeLa cells. We conclude that rAAV1, 2, and 5 utilize distinct mechanisms for intracellular trafficking, and that post-nuclear events play an important role in determining the efficiency of HeLa cell transduction by these serotypes. Thus, overcoming post-nuclear barriers that limit uncoating and/or promote virion degradation may enhance the efficiency of certain AAV serotypes. Keiser and colleagues investigate differences in viral entry, intracellular trafficking, and nuclear import between recombinant adeno-associated virus (AAV) serotypes 1, 2, and 5 that might define their transduction efficiency in HeLa cells. The authors found that the three serotypes use distinct mechanisms for intracellular trafficking, and that post-nuclear entry events such as uncoating or virion degradation are important in determining transduction efficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 2×
“It is likely that uncoating of the AAV capsid takes place following import of the virus into the nucleus, although data on this from different groups are contradictory (Bartlett et al. , 2000; Sanlioglu et al. , 2000; Seisenberger et al. , 2001; Xiao et al. , 2002; Lux et al. , 2005).”
InfluentialNew recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391 · cited 3×
“The intracellular trafficking of rAAV2/2 has been shown to be quite slow (Duan et al. , 2000; Hansen et al. , 2000), and enhancement of this process with proteasome inhibitors can facilitate viral movement to the nucleus and enhance transduction (Duan et al. , 2000; Yan et al. , 2002, 2004).”
Self-citationThomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358 · cited 8×
“In hepatocytes, for example, both rAAV2/2 and rAAV2/8 efficiently enter the nucleus, but rAAV2/8 appears to uncoat much more rapidly than rAAV2/2, and this is thought to account for greater levels of hepatic transduction by rAAV2/8 (Thomas et al. , 2004).”
InfluentialGirod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-5-973 · Cited by 354 · cited 1×
“Endosomal escape of rAAV2 is thought to involve a change in the conformation of the viral capsid, such that an otherwise buried phospholipase A2 domain in VP1 becomes exposed (Girod et al. , 2002; Kronenberg et al. , 2005; Mani et al. , 2006).”
Intracellular trafficking of adeno-associated viral vectors
Ding, W., Zhang, L., Yan, Z., & Engelhardt, J. F. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302527 · Cited by 251
Self-citationYan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2043-2053.2002 · Cited by 222
Self-citationKronenberg, S., Böttcher, B., von der Lieth, C. W., Bleker, S., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5296-5303.2005 · Cited by 198 · cited 1×
“Endosomal escape of rAAV2 is thought to involve a change in the conformation of the viral capsid, such that an otherwise buried phospholipase A2 domain in VP1 becomes exposed (Girod et al. , 2002; Kronenberg et al. , 2005; Mani et al. , 2006).”
AAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191 · cited 1×
“Additionally, directed evolution approaches and hybrid capsid construction have greatly expanded the capabilities of the rAAV vectors (Choi et al. , 2005; Vanden-berghe et al. , 2009).”
Tailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
Yan, Z., Zak, R., Zhang, Y., Ding, W., Godwin, S., Munson, K., Peluso, R., & Engelhardt, J. F. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.2863-2874.2004 · Cited by 138 · cited 1×
“The intracellular trafficking of rAAV2/2 has been shown to be quite slow (Duan et al. , 2000; Hansen et al. , 2000), and enhancement of this process with proteasome inhibitors can facilitate viral movement to the nucleus and enhance transduction (Duan et al. , 2000; Yan et al. , 2002, 2004).”
Self-citationGrieger, J. C., Johnson, J. S., Gurda-Whitaker, B., Agbandje-McKenna, M., & Samulski, R. J. (2007) · Journal of Virology · doi:10.1128/jvi.00580-07 · Cited by 83 · cited 2×
“This conformational change is also thought to expose a nuclear localization signal within the capsid, promoting import of the virus into the nucleus following its release into the cytoplasm (Grieger et al., 2007).”
Influential
Cited by
Microvesicle-associated AAV Vector as a Novel Gene Delivery System
Maguire, C. A., Balaj, L., Sivaraman, S., Crommentuijn, M. H., Ericsson, M., Mincheva-Nilsson, L., Baranov, V., Gianni, D., Tannous, B. A., Sena-Esteves, M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.303 · Cited by 283
Intracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258
Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Nieuwenhuis, B., Haenzi, B., Hilton, S., Carnicer-Lombarte, A., Hobo, B., Verhaagen, J., & Fawcett, J. W. (2021) · Gene Therapy · doi:10.1038/s41434-020-0169-1 · Cited by 114
Metadata
- Authors
- Keiser, N. W., Yan, Z., Zhang, Y., Lei-Butters, D. C. M., & Engelhardt, J. F.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2011-11
- Volume
- 22
- Issue
- 11
- Pages
- 1433-1444
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2044291926
- Cited by
- 40
- References
- 12
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.